|
rs121917887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs201216664
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs587782529
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.
|
9704931 |
1998 |
|
rs367597251
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Taken together, our results demonstrate that mutant C174Y possesses features that can positively contribute to cancer progression.
|
11004663 |
2000 |
|
rs1443465532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results demonstrate that P125A endostatin inhibits the angiogenic switch during mammary gland adenocarcinoma tumor progression in the C3(1)/Tag transgenic model.
|
12209972 |
2002 |
|
rs137852578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Human LNCaP cells, extensively used as a model for androgen-dependent prostate tumor, express the androgen receptor (AR) mutant T877A promiscuously transactivated by estrogens and other ligands, which may further facilitate cancer progression.
|
12391264 |
2002 |
|
rs351855
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used.
|
14710228 |
2004 |
|
rs17217772
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |
|
rs4987188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |
|
rs1057519710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of a 17-cm malignant GIST in the index patient revealed that it was hemi/homozygous for the germline D820Y mutation, indicating loss of the remaining wild-type KIT allele with tumor progression.
|
16327443 |
2005 |
|
rs758272654
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015).
|
16467086 |
2006 |
|
rs3136797
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the polbeta gene: a Pro --> Arg change at codon 242 (the Pro242Arg polymorphism) and a Lys --> Met change at codon 289 (the Lys289Met polymorphism) and breast cancer risk and cancer progression.
|
17131038 |
2007 |
|
rs587782148
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sequencing of margins with dysplasia demonstrated an identical nonconservative mitochondrial mutation (A76T in ND4L) as the tumor, suggesting a role of mtDNA mutation in tumor progression.
|
17456604 |
2007 |
|
rs1800470
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The C allele of the Leu10Pro polymorphism may predispose men to a more rapid cancer progression.
|
18058470 |
2007 |
|
rs1800206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Frequent occurrence of advanced disease in patients with L162V polymorphism suggests a role for this polymorphism in tumor progression.
|
19119483 |
2008 |
|
rs1288373809
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
rs375874539
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
rs758272654
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers.
|
20027678 |
2009 |
|
rs2227983
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The common EGFR-R521K genotype (G/G) was significantly associated with increased skin toxicity (P = 0.024) and showed a trend toward reduced risk of tumor progression (hazard ratio, 0.55; 95% confidence interval, 0.27-1.08; P = 0.08), whereas no correlation of the EGFR-R521K genotype with OS could be observed (P = 0.20).
|
20028750 |
2010 |
|
rs1284806277
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1285136498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs.
|
20498063 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs.
|
20498063 |
2010 |